Wound Care News

Industry News's picture
Keywords: 

By Industry News

Sarasota, FL, September 2, 2021—Omeza, a skin science company, announced that the U.S. Food and Drug Administration (FDA) cleared Omeza® Collagen Matrix through the FDA 510(k) premarket notification process. Omeza® Collagen Matrix is Omeza’s first Rx product, and the first drug/device combination matrix of its kind for chronic wound care.

Blog Category: 
Industry News's picture
Keywords: 

Wound Care News

Toronto, ONTARIO and Las Vegas, NEVADA– (October 28, 2021 -MolecuLight Inc., a provider of in point-of-care fluorescence imaging for the detection of wounds that contain elevated bacterial loads, announces the presentation of 7 clinical posters and presentations at the Symposium of Wound Care (SAWC) Fall 2021, held from October 29 – 31, 2021 in Las Vegas, Nevada.

Blog Category: 
Industry News's picture
Keywords: 

By Industry News

Jacksonville, FL – Oct. 27, 2021 – Next Science Limited, a medical technology company, announced that it will exhibit at the Symposium on Advanced Wound Care Fall meeting (SAWC Fall) from Oct. 29-31. Next Science, whose mission is to heal patients and save lives by addressing the impact of biofilms on human health, will exhibit at Booth No. 718.

Blog Category: 
Industry News's picture
Keywords: 

By Industry News

Toronto, Canada– September 23, 2021 – MolecuLight Inc., the creator of a point-of-care fluorescence imaging device for real-time detection of wounds containing elevated bacterial loads, announces that it has received FDA 510(k) clearance for the detection of wounds containing clinically significant levels (>104 CFU/g) of Pseudomonas aeruginosa (PA) for the previously cleared MolecuLight i:X imaging device. The i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria. This new FDA clearance supports the ability of the i:X device to increase the clinician’s ability to detect the presence of Pseudomonas aeruginosa in wounds using the cyan fluorescence signal. This augmented labeling is based on a detailed retrospective statistical analysis of over 350 patients.

Blog Category: 
Industry News's picture
Keywords: 

By Industry News

San Antonio, TX – September 21, 2021 – MDM Wound Ventures Inc., the manufacturer of EZ Debride, is announcing Dr. Thomas Serena has agreed to the position of Clinical and Research Director at MDM Wound Ventures, Inc.

Blog Category: 
Industry News's picture

By Industry News

San Antonion, TX – September 2021 – EO2 Concepts® announced today the release of a new, larger wound dressing for post-surgical dehiscence and large, painful leg ulcers. This new 5x7 OxySpur® oxygen diffusion dressing is part of the OxyGeni® System which provides a complete oxygen therapy and wound monitoring system. Continuous Diffusion of Oxygen (CDO) therapy provides full closure and pain relief to patients dealing with chronic, ischemic or surgical wounds.

Blog Category: 
Industry News's picture

By Industry News

Summit facilitated cross-collaboration among physicians and surgeons exploring advances in patient care using cryopreserved amniotic membrane allografts

Blog Category: 
Industry News's picture

By Industry News

McDonough, GA – September 9, 2021 – Encompass Group, LLC, a manufacturer and marketer of professional healthcare apparel, patient warming solutions, therapeutic support surfaces, and healthcare textiles, announced that it has received Issuance of Patent for Airisana® as recognized by the U.S. Patent and Trademark Office (USPTO).

Blog Category: 
Industry News's picture
Keywords: 

September 1, 2021 – San Antonio, TX – EZ Debride, a registered and patented brand of MDM Wound Ventures Inc. developed and manufactured out of San Antonio and Kerrville, Texas, is announcing the distribution agreement with UCT Medical Co Ltd. Seoul, South Korea and with Intega Healthcare, Singapore.

Blog Category: 
Industry News's picture
Keywords: 

By Industry News

Jacksonville, FL – August 11, 2021 – Next Science Limited pleased to announce that a clinical trial has been initiated in the U.S. for XPERIENCE™ No Rinse Antimicrobial Solution. Enrollment in the 30-patient, 90-day study is currently underway.

Blog Category: